Moving towards clinical trials for mitochondrial diseases

Area of Science:

• Biochemistry
• Genetics
• Clinical Medicine

Background:

• Primary mitochondrial diseases are common, severe inherited metabolic disorders affecting ~1 in 4,300 live births.
• Current management is largely supportive due to clinical and molecular diversity and a lack of disease-modifying therapies.
• Clinical trials have faced challenges including ineffective compounds, limited natural history data, and a lack of biomarkers and outcome measures.

Purpose of the Study:

• To review current treatments and management strategies for mitochondrial diseases.
• To evaluate challenges and propose solutions for clinical trial design in mitochondrial diseases.
• To highlight emerging pharmacological and genetic therapies progressing to clinical trials.

Main Methods:

• Literature review of current treatments and management strategies.
• Analysis of challenges and potential solutions for clinical trial design.
• Overview of preclinical and early-phase human interventional studies for novel therapies.

Main Results:

• Significant advances in therapy development over the past decade.
• Numerous small molecules are transitioning from preclinical to early-phase human studies.
• Emerging pharmacological and genetic strategies show potential for treating mitochondrial diseases.

Conclusions:

• Despite challenges, progress in therapy development for mitochondrial diseases is encouraging.
• Novel pharmacological and genetic approaches are advancing towards clinical application.
• Improved trial design, supported by better data and biomarkers, is crucial for future success.